Diabetes
Diabetes Market Forecast to 2013
| Publication Date | November 2008 |
| Publisher | Cutting Edge Information |
| Product Type | Report |
| Pages | 258 |
| ISBN Number | not applicable |
| Product Code | CUT00066 |
Price
approximately: $9,995 | €7,270
print £7,830 ($11,993 | €8,725)
Order above formats by FAX
Summary
Which companies are poised to dominate the diabetes market? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety issues affect drug profitability over the long term?
CEI's veteran analysts answer these questions - and more - by placing critical drug information in a relevant industry-wide context. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers - all in one, easy-to-read format.
From showing the most accurate sales projections and pipelines to identifying market threats and opportunities, ""Diabetes Market Forecast to 2013"" provides teams with a hard-hitting, penetrating analysis of the global diabetes market. For reliable evidence to support key resource allocation decisions, this is the only resource you'll need.
Diabetes Portfolio Profiles
- Amylin
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Novo Nordisk
- Sanofi-Aventis
- Takeda
Contents
- Type I Antidiabetic Treatments
- Traditional Insulins
- Novolin
- Humulin
- ShortActing Insulin Analogs
- Novolog
- Humalog
- Apidra
- LongActing Insulin Analogs
- Levemir
- Lantus
- Other Drugs
- Symlin
- Technosphere
- Teplizumab
- Otelixuzumab
- TT223
- Type II Antidiabetic Treatments
- DPP4 Inhibitors
- Januvia (includes Janumet)
- Galvus (includes Eucreas)
- Alogliptin
- Onglyza
- GLP1 Analogs
- Byetta (includes Byetta LongActing Release)
- Liraglutide
- AVE0010
- Syncria
- Tapsoglutide
- SGLT2 Inhibitors
- AVE2268
- Remogliflozin
- Dapagliflozin
- Sulfonylureas
- Amaryl
- Glucotrol
- Thiazolidinediones (TZDs)
- Avandia (includes Avandamet and Avandaryl)
- Actos (includes Actoplus Met and Duetact)
- Meglitinides
- Prandin
- Starlix
- Glufast
- AlphaGlucosidase Inhibitors
- Precose
- Glyset
- Other
- Acomplia
- MBX102
- AGI1067
- XOMA052
- SRT501
- MB07803
- ISIS113715
- Adjunct Therapies
- Cymbalta
- Arxxant
- Avapro
- Cozaar
- Lyrica
- Zyvox
- Regranex
- Lucentis
- Atacand
- Epicept NP1
- Qnexa
- Product Profile Components
- Drug's development and approval history
- Competitive and strategic positioning
- Current status of drug, including approval history
- Current and projected competitive strengths/vulnerabilities
- Current and projected sales position within class
- Market growth opportunities
- Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events
- Sales projection charts for next 47 years
- Materiality charts (drug's percentage of company revenue) for 2007 and 2012
- Patents and generics charts containing market exclusivity and patent information for approved drugs
- Clinical trial data tables
- Summary of most important trials
- Trial title and objective
- Start and end dates
